tiprankstipranks
Advertisement
Advertisement
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial
PremiumCompany AnnouncementsGain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial
2M ago
Gain Therapeutics receives FDA clearance of GT-02287 IND application
Premium
The Fly
Gain Therapeutics receives FDA clearance of GT-02287 IND application
2M ago
Gain Therapeutics Shareholders Confirm Board and Auditor Choices
Premium
Company Announcements
Gain Therapeutics Shareholders Confirm Board and Auditor Choices
2M ago
Buy Rating Reaffirmed on Encouraging GT-02287 Parkinson’s Data and Upcoming Catalysts; 12‑Month Price Target Maintained at $7
PremiumRatingsBuy Rating Reaffirmed on Encouraging GT-02287 Parkinson’s Data and Upcoming Catalysts; 12‑Month Price Target Maintained at $7
3M ago
Gain Therapeutics price target lowered to $8 from $10 at Roth Capital
Premium
The Fly
Gain Therapeutics price target lowered to $8 from $10 at Roth Capital
3M ago
Gain Therapeutics reports Q1 EPS (13c), consensus (14c)
Premium
The Fly
Gain Therapeutics reports Q1 EPS (13c), consensus (14c)
3M ago
Gain announces presentations on Phase 1b clinical study of GT-02287
PremiumThe FlyGain announces presentations on Phase 1b clinical study of GT-02287
5M ago
Gain Therapeutics, Inc. (GANX) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Gain Therapeutics, Inc. (GANX) Q4 Earnings Cheat Sheet
5M ago
Gain Therapeutics provides regulatory update on GT-02287
Premium
The Fly
Gain Therapeutics provides regulatory update on GT-02287
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100